Managing patients with hematological malignancies during COVID-19 pandemic

Abstract

The outbreak of the coronavirus disease 2019 (COVID‐19) has posed an unprecedented challenge to the health care communities across the globe. As of June 17th, 2020, a total of 8,339,829 confirmed COVID-19 cases with 448,420 deaths have been reported [2]. Different parts of the world are seeing different levels of COVID-19 activity with regards to the infection rate, susceptible population, and mortality rate. The COVID-19 pandemic is a rapidly evolving emergency and is a subject of regular debate and advanced research. Patients with hematological disorders and solid malignancies have special needs and oncologists are facing a compound challenge.